Other

Distributions of earnings from equity method investees

Royalty Pharma Distributions of earnings from equity method investees decreased by 72.2% to $3.72M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 72.2%, from $13.40M to $3.72M. Over 2 years (FY 2021 to FY 2023), Distributions of earnings from equity method investees shows a downward trend with a -26.0% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
Metric ID: other_equity_method_investment_dividends_or_distributions

Historical Data

14 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q1 '25Q1 '26
Value$4.68M$6.21M$6.17M$20.69M$6.81M$5.81M$5.83M$16.27M$2.24M$313.00K$0.00$13.40M$13.40M$3.72M
QoQ Change—+32.7%-0.6%+235.3%-67.1%-14.7%+0.2%+179.2%-86.2%-86.0%-100.0%—+0.0%-72.2%
YoY Change————+45.6%-6.4%-5.6%-21.4%-67.1%-94.6%-100.0%-17.6%+0.0%-72.2%
Range$0.00 – $20.69M
CAGR-6.8%
Avg YoY Growth-33.9%
Median YoY Growth-19.5%

Frequently Asked Questions

What is Royalty Pharma's distributions of earnings from equity method investees?
Royalty Pharma (RPRX) reported distributions of earnings from equity method investees of $3.72M in Q1 2026.
How has Royalty Pharma's distributions of earnings from equity method investees changed year-over-year?
Royalty Pharma's distributions of earnings from equity method investees decreased by 72.2% year-over-year, from $13.40M to $3.72M.
What is the long-term trend for Royalty Pharma's distributions of earnings from equity method investees?
Over 2 years (2021 to 2023), Royalty Pharma's distributions of earnings from equity method investees has grown at a -26.0% compound annual growth rate (CAGR), from $34.38M to $18.82M.